This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arena Pharmaceuticals (ARNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
A Company's First Profit Can Mean Big Profits for Investors
by Benjamin Rains
Obviously, losing less money than the prior quarter is a positive sign, as it shows growth. Then firms hit a point where they grow and grow and eventually become profitable. These are the stocks that will likely see more demand from new investors...
Why Is Arena Pharmaceuticals (ARNA) Up 9.1% Since Last Earnings Report?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.
Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Why Is Arena Pharmaceuticals (ARNA) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 New Small Cap ETFs on the Block
by Zacks Equity Research
Prudential's PGIM launches two actively managed smart-beta ETFs.
Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal
by Zacks Equity Research
Regulatory news and licensing contracts are key highlights in the biotech sector this week.
Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
by Zacks Equity Research
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.
Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate
by Zacks Equity Research
Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.
Why Is Arena Pharmaceuticals (ARNA) Up 7.4% Since Last Earnings Report?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
Arena Pharmaceuticals (ARNA) Up 15.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More
by Zacks Equity Research
The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.